Evidence map›Paper›PMID 34835455›Full record

ReviewMicroorganisms2021

Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery.

Antonia Molloy, James Harrison, John S McGrath, Zachary Owen, Clive Smith, Xin Liu, Xin Li, Jonathan A G Cox

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Future Research Directions on Mycobacterium tuberculosis Proteins.Advances in experimental medicine and biology · 2026
    Review
  2. Review
  3. Review
  4. Recent advances in electrochemiluminescence sensing for in vitro cell analysis: a review.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. The evolving biology ofFrontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Antonia MolloySchool of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK.
James HarrisonSchool of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK.
John S McGrathSphere Fluidics Limited, The McClintock Building, Suite 7, Granta Park, Great Abington, Cambridge CB21 6GP, UK.ORCID 0000-0001-9110-7759
Zachary OwenSphere Fluidics Limited, The McClintock Building, Suite 7, Granta Park, Great Abington, Cambridge CB21 6GP, UK.ORCID 0000-0002-5591-2029
Clive SmithSphere Fluidics Limited, The McClintock Building, Suite 7, Granta Park, Great Abington, Cambridge CB21 6GP, UK.
Xin LiuSphere Fluidics Limited, The McClintock Building, Suite 7, Granta Park, Great Abington, Cambridge CB21 6GP, UK.
Xin LiSphere Fluidics Limited, The McClintock Building, Suite 7, Granta Park, Great Abington, Cambridge CB21 6GP, UK.
Jonathan A G CoxSchool of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK.ORCID 0000-0001-5208-4056

Funding

Engineering and Physical Sciences Research Council EP/S02347X/1
6 · The paper itself

Abstract

Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen

Indexed as

antibioticsantimicrobial resistancebioengineered modelsdiagnosticsdrug discoverymicrofluidicsMycobacteriumsingle-cell analysistuberculosis

Identifiers

PMID34835455
PMCPMC8618277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.